DK0569583T3 - Controlled use of polyether-substituted tumor agents in diagnosis and therapy - Google Patents

Controlled use of polyether-substituted tumor agents in diagnosis and therapy

Info

Publication number
DK0569583T3
DK0569583T3 DK93901669T DK93901669T DK0569583T3 DK 0569583 T3 DK0569583 T3 DK 0569583T3 DK 93901669 T DK93901669 T DK 93901669T DK 93901669 T DK93901669 T DK 93901669T DK 0569583 T3 DK0569583 T3 DK 0569583T3
Authority
DK
Denmark
Prior art keywords
radio
substituted
phthalocyanine
polyethylene glycol
tumour
Prior art date
Application number
DK93901669T
Other languages
Danish (da)
Inventor
Georgi Graschew
Hans-J Sinn
Hans-Hermann Schrenk
Wolfgang Maier-Borst
Eckhard Friedrich
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4139715A external-priority patent/DE4139715C2/en
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK0569583T3 publication Critical patent/DK0569583T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Tumour active or tumour diagnostic compound (I), which concentrates in the tumour, is coupled to a compound (II), with at least two phenolic OH groups or at least one aliphatic amino group, where at least 2 OH or at least 1 NH2 groups are substituted with a polyethylene glycol chain whose polymerisation degree, n, is 5-250, and whose terminal OH group is substituted with a 1-12C alkyl ester or ether. Preferably n = 10-200 (100-110) and (I) is a cis-platin compound, tetracycline, steroid, porphin, phthalocyanine or a conventional X-ray contrast agent. (I) is formed by reacting (II) with the polyethylene glycol ester or ether (III) in solution. When (III) has a molecular weight of more than 5000 (especially more than 10,000) it is activated with cyanuric chloride. - (I) may be radio-labelled, especially as Gd-phthalocyanine metal complexes, Dy164 derivatives of e.g. phthalocyanine or radiolabelled diphosphonates for radiotherapy with L131 or L125, or are conjugated to give radio-iodo, radio-bromo or radio-metal ion activated peptides, porphins or phthalocyanines. Highly iodo-substituted compounds especially porphins and tyrosine oligomers, and boric acid esters, luminols, and radiosensitisers especially nitroimidazoles, in the form of polyethylene glycol derivatives, are also claimed.
DK93901669T 1991-12-02 1992-12-02 Controlled use of polyether-substituted tumor agents in diagnosis and therapy DK0569583T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4139715A DE4139715C2 (en) 1990-05-30 1991-12-02 Controlled use of polyether-substituted tumor agents in diagnosis and therapy
PCT/EP1992/002789 WO1993010743A2 (en) 1991-12-02 1992-12-02 Controlled use of polyether-substituted tumor agents in diagnosis and therapy

Publications (1)

Publication Number Publication Date
DK0569583T3 true DK0569583T3 (en) 2001-11-12

Family

ID=6446090

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93901669T DK0569583T3 (en) 1991-12-02 1992-12-02 Controlled use of polyether-substituted tumor agents in diagnosis and therapy

Country Status (9)

Country Link
EP (1) EP0569583B1 (en)
JP (1) JPH06509117A (en)
AT (1) ATE203681T1 (en)
DE (2) DE4017439C2 (en)
DK (1) DK0569583T3 (en)
ES (1) ES2163406T3 (en)
GR (1) GR3037077T3 (en)
PT (1) PT569583E (en)
WO (1) WO1993010743A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2640293B2 (en) * 1990-05-30 1997-08-13 ドイチエス クレープスフオルシユングスツエントルム ステイフツング デス アフエントリヒエン レヒトス Polyether-substituted antitumor agent
DE4017439C2 (en) * 1990-05-30 1994-06-23 Deutsches Krebsforsch Polyether-substituted tumor agents
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
DE4435087A1 (en) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Conjugate for the treatment of infectious, autoimmune and skin diseases
DE19514087A1 (en) * 1995-04-13 1996-10-17 Deutsches Krebsforsch Conjugate of an active ingredient, a polyether and possibly a native protein that is not considered foreign to the body
DE19548114C2 (en) 1995-12-21 2000-04-27 Deutsches Krebsforsch Conjugate comprising an active ingredient, a polypeptide and a polyether
DE19627164C2 (en) * 1996-07-05 1998-09-24 Deutsches Krebsforsch Production of polyether-containing chlorins and bacteriochlorins, such compounds and their use
ATE257014T1 (en) * 1997-04-29 2004-01-15 Amersham Health As LIGHT IMAGING CONTRAST AGENTS
DE10162521A1 (en) * 2001-12-19 2003-07-17 Goetz Nowak Use of molecular weight-expanded substances in tumor therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062933A (en) * 1975-05-27 1977-12-13 Mallinckrodt, Inc. Colloidal compositions with protective agents suitable for radioactive labeling
US4684728A (en) * 1979-01-12 1987-08-04 Bayer Aktiengesellschaft Solubilizing biologically active compounds with reactive hydrogen atoms
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4830847A (en) * 1985-06-28 1989-05-16 The Procter & Gamble Company Diphosphonate-derivatized macromolecules
DE3701665A1 (en) * 1987-01-19 1988-07-28 Schering Ag POLYMER COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
DE3809671A1 (en) * 1988-03-18 1989-09-28 Schering Ag PORPHYRINE COMPLEX COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
DE4017439C2 (en) * 1990-05-30 1994-06-23 Deutsches Krebsforsch Polyether-substituted tumor agents

Also Published As

Publication number Publication date
WO1993010743A3 (en) 1993-07-08
DE4017439A1 (en) 1991-12-05
EP0569583B1 (en) 2001-08-01
EP0569583A1 (en) 1993-11-18
DE59209911D1 (en) 2001-09-06
PT569583E (en) 2002-01-30
GR3037077T3 (en) 2002-01-31
WO1993010743A2 (en) 1993-06-10
ATE203681T1 (en) 2001-08-15
DE4017439C2 (en) 1994-06-23
ES2163406T3 (en) 2002-02-01
JPH06509117A (en) 1994-10-13

Similar Documents

Publication Publication Date Title
KR920700205A (en) Tri-aza macrocycle compounds and their metal complexes
DK0569583T3 (en) Controlled use of polyether-substituted tumor agents in diagnosis and therapy
AU703057B2 (en) Improvements in or relating to organic compounds
ZA919221B (en) Drug delivery porphyrin compositions and methods
FI935878A (en) PORFYCENFOERENINGAR FOER FOTODYNAMISK TERAPI
KR970701193A (en) Texaphyrin metal complexes having improved functionalization
ATE142508T1 (en) CONTRAST AGENTS
US5622685A (en) Polyether-substituted porphyrin anti-tumor agents
KR900006273A (en) Chelants having ortho-binding functional groups and complexes thereof
US6395254B1 (en) Conjugate comprising an active agent, a polypeptide and a polyether
JPH05501885A (en) Polyether substituted antitumor agent
DK0570575T3 (en) Bicycloazamacrocyclophosphonic acid, complexes, conjugates, contrast agents and preparation thereof
SE9803482D0 (en) Ion exchange tumor targeting (IETT)
ES2107030T3 (en) 1,1,2-TRIFENILBUTENOS SUBSTITUTED AND ITS USE IN THE TREATMENT AND DIAGNOSIS OF CANCER.
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
MY141501A (en) Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents and processes for their preparation